Abstract
Summary
This study investigated the bone of HIV patients both in terms of quantity and quality. It was found that HIV-infected patients did fracture independently of the degree of bone demineralization as in other forms of secondary osteoporosis.
Introduction
We aimed to determine the prevalence of vertebral fractures (VFs) in HIV patients who were screened by bone mineral density (BMD) and to explore possible factors associated with VFs.
Methods
This is a cross-sectional study that included HIV-infected patients recruited in the Clinic of Infectious and Tropical Diseases and that underwent BMD measurement by dual-energy X-ray absorptiometry (DXA) at the lumbar spine and hip (Lunar Prodigy, GE Healthcare). For the assessment of VFs, anteroposterior and lateral X-ray examinations of the thoracic and lumbar spines were performed and were centrally digitized. Logistic regression models were used in the statistical analysis of factors associated with VFs.
Results
One hundred thirty-one consecutive patients with HIV infection (93 M, 38 F, median age 51 years; range, 36-75) underwent BMD measurement: 25.2 % of patients showed normal BMD, while 45 % were osteopenic and 29.7 % osteoporotic. Prevalence of low BMD (osteopenia and osteoporosis) was higher in females as compared to males (90 vs 69 %) with no significant correlation with age and body mass index. VFs occurred more frequently in patients with low BMD as compared to patients with normal BMD (88.5 vs. 11.4 %; p < 0.001) without any significant difference between osteopenia and osteoporosis (43 vs. 46 %; p = 0.073). VFs were significantly associated with older age and previous AIDS events.
Conclusions
These results suggest a BMD <−1 threshold to identify patients at risk of skeletal fragility and, therefore, good candidates for morphometric evaluation of spine X-ray in line with other forms of secondary osteoporosis with impaired bone quality.
Similar content being viewed by others
References
Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21:617–623
Amiel C, Ostertag A, Slama L, Baudoin C, N’Guyen T, Lajeunie E et al (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19:402–409
Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L et al (2010) High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24:2827–2833
Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17:1917–1923
Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N et al (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22:395–402
Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL et al (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14:F63–F67
Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN et al (2001) Reduced bone mineral density in HIV-positive individuals. AIDS 15:1731–1733
Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15:807–808
Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S et al (2006) Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 38:893–897
Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20:2165–2174
Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2006) Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol 65:191–197
Jacobson DL, Spiegelman D, Knox TK, Wilson IB (2008) Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 49:298–308
Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B et al (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6:e17217
Briot K, Kolta S, Flandre P, Boue F, Van Ngo P, Cohen-Codar I et al (2011) Prospective one-year bone loss in treatment-naive HIVR men and women on single or multiple drug HIV therapies. Bone 48:1133–1139
Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL et al (2009) Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 23:817–824
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191–201
Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curie M, Goyenechea A, Fernandez-Guerrero M (2008) Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 9:89–95
Van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE et al (2009) First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 23:1367–1376
McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P et al (2011) Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224 s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801
Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB et al (2007) Bone mineral density remains stable in HAART treated HIV-infected men over 2 years. Clin Endocrinol 67:270–275
Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D et al (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36:482–490
Nolan D, Upton R, McKinnon E, John M, James I, Adler B et al (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15:1275–1280
Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475
Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM, Fordham JN et al (2008) Peripheral dual-energy X-ray absorptiometry in the management of osteoporosis: the 2007 ISCD Official Positions. J Clin Densitom 11:188–206
Griffith JF, Genant HK (2012) New advances in imaging osteoporosis and its complications. Endocrine 42:39–51
McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS et al (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51:937–946
Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205:S391–S398
Torti C, Mazziotti G, Soldini PA, Focà E, Maroldi R, Gotti D et al (2012) High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41:512–517
Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767
European AIDS Clinical Society (2013) Prevention and management of non-infectious comorbidities in HIV. Version 7.0. http://eacsociety.org/Guidelines.aspx. Accessed 17 Jul 2014)
Pepe J, Isidori AM, Falciano M, Iaiani G, Salotti A, Diacinti D et al (2012) The combination of FRAX and Ageing Male Symptoms scale better identifies treated HIV males at risk for major fracture. Clin Endocrinol 77:672–678
Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41:58–69
Oleksik A, Ott SM, Vedi S, Bravenboer N, Compston J, Lips P (2000) Bone structure in patients with low bone mineral density with or without vertebral fractures. J Bone Miner Res 15:1368–1375
Mazziotti G, Bianchi A, Bonadonna S et al (2008) Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 93:4649–4655
Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39:253–259
Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328
Mazziotti G, Porcelli T, Bianchi A, Cimino V, Patelli I, Mejia C et al (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol 163:15–20
Mazziotti G, Porcelli T, Mormando M, De Menis E, Bianchi A, Mejia C et al (2011) Vertebral fractures in males with prolactinoma. Endocrine 39:288–293
Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A et al (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402–3410
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503
Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526
Wanner DP, Tyndall A, Walker UA (2009) Tenofovir-induced osteomalacia. Clin Exp Rheumatol 27:1001–1003
Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J et al (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 57:1483–1488
Brown TT (2013) HIV: an under-recognized secondary cause of osteoporosis? J Bone Miner Res 28:1256–1258
Maffezzoni F, Porcelli T, Karamouzis I et al (2014) Osteoporosis in human immunodeficiency virus patients—an emerging clinical concern. Eur Endocrinol 10:79–83
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Porcelli, T., Gotti, D., Cristiano, A. et al. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporos Int 25, 2263–2269 (2014). https://doi.org/10.1007/s00198-014-2760-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-014-2760-z